Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, 03722, Republic of Korea.
Department of Molecular Microbiology and Immunology, Brown University, Providence, RI, 02912, USA.
Exp Mol Med. 2024 Jul;56(7):1501-1512. doi: 10.1038/s12276-024-01262-7. Epub 2024 Jul 1.
Recent substantial evidence implicating commensal bacteria in human diseases has given rise to a new domain in biomedical research: microbiome medicine. This emerging field aims to understand and leverage the human microbiota and derivative molecules for disease prevention and treatment. Despite the complex and hierarchical organization of this ecosystem, most research over the years has relied on 16S amplicon sequencing, a legacy of bacterial phylogeny and taxonomy. Although advanced sequencing technologies have enabled cost-effective analysis of entire microbiota, translating the relatively short nucleotide information into the functional and taxonomic organization of the microbiome has posed challenges until recently. In the last decade, genome-resolved metagenomics, which aims to reconstruct microbial genomes directly from whole-metagenome sequencing data, has made significant strides and continues to unveil the mysteries of various human-associated microbial communities. There has been a rapid increase in the volume of whole metagenome sequencing data and in the compilation of novel metagenome-assembled genomes and protein sequences in public depositories. This review provides an overview of the capabilities and methods of genome-resolved metagenomics for studying the human microbiome, with a focus on investigating the prokaryotic microbiota of the human gut. Just as decoding the human genome and its variations marked the beginning of the genomic medicine era, unraveling the genomes of commensal microbes and their sequence variations is ushering us into the era of microbiome medicine. Genome-resolved metagenomics stands as a pivotal tool in this transition and can accelerate our journey toward achieving these scientific and medical milestones.
近年来,大量证据表明共生细菌与人类疾病有关,这促使了一个新的生物医学研究领域的出现:微生物组医学。这个新兴领域旨在理解和利用人类微生物群及其衍生分子来预防和治疗疾病。尽管这个生态系统具有复杂的层次结构,但多年来的大多数研究都依赖于 16S 扩增子测序,这是细菌系统发育和分类学的遗留问题。尽管先进的测序技术使整个微生物组的成本效益分析成为可能,但将相对较短的核苷酸信息转化为微生物组的功能和分类组织,直到最近才提出了挑战。在过去的十年中,旨在直接从全宏基因组测序数据中重建微生物基因组的基因组解析宏基因组学取得了重大进展,并继续揭示各种与人类相关的微生物群落的奥秘。全宏基因组测序数据的数量迅速增加,同时在公共存储库中也汇编了新的宏基因组组装基因组和蛋白质序列。这篇综述概述了基因组解析宏基因组学在研究人类微生物组方面的能力和方法,重点研究了人类肠道的原核微生物组。正如解码人类基因组及其变异标志着基因组医学时代的开始一样,揭示共生微生物的基因组及其序列变异将引领我们进入微生物组医学时代。基因组解析宏基因组学是这一转变的关键工具,可以加速我们实现这些科学和医学里程碑的进程。